A 63-year-old man in Norway has achieved long-term remisión del VIH tras un trasplante de células madre, marking a significant medical milestone as the first known case of this outcome resulting from a sibling donor. The case, now referred to as the “Oslo patient,” was detailed in a study published in the journal Nature Microbiology, highlighting a rare convergence of genetic luck and critical oncology treatment.
The patient, who has lived with the human immunodeficiency virus (HIV) since 2006, did not undergo the procedure to cure his HIV, but to save his life from a different threat. In 2017, he was diagnosed with myelodysplastic syndrome, a potentially fatal form of blood cancer. The subsequent stem cell transplant, performed in November 2020, unexpectedly cleared the virus from his system, allowing him to stop antiretroviral therapy (ART) two years later.
This case brings the total number of people globally known to have achieved HIV remission following stem cell transplants to approximately 10. While these instances provide a blueprint for potential future cures, medical experts emphasize that the procedure remains an extreme intervention, unsuitable for the vast majority of people living with the virus.
A Genetic Doorway Locked
The success of the transplant hinged on a specific genetic anomaly. Most HIV strains enter immune cells through a receptor called CCR5. However, some individuals possess a mutation known as CCR5Δ32, which effectively removes this “doorway,” making the cells resistant to the virus.
Initially, the medical team at Oslo University Hospital sought an external donor with this mutation. When no such match was found, they prioritized the urgent treatment of the patient’s cancer and proceeded with a transplant from his 60-year-old brother. It was only just before the procedure that doctors discovered the brother was not only an immunological match but also a carrier of the CCR5 mutation.
“No teníamos ni idea… Eso fue increíble,” said Dr. Anders Eivind Myhre of Oslo University Hospital, describing the clinical surprise of the sibling’s genetic profile.
The result was a phenomenon called “complete chimerism.” In this state, the patient’s original immune system was entirely replaced by the donor’s. Crucially, this replacement occurred not only in the blood and bone marrow but also in the intestines—the body’s primary reservoir where HIV typically hides and persists even during treatment.
Analyzing the Depth of Remission
To determine if the patient was truly in remission, researchers conducted exhaustive testing. They examined tens of millions of immune cells and found no intact viral DNA and no virus capable of replication. The patient’s body no longer showed a specific immune response to HIV, suggesting the virus had been effectively erased from his biological memory.
The distinction between “remission” and a “cure” is a careful one in medical literature. While Dr. Myhre noted that for all practical purposes the patient appears cured, the scientific community continues to monitor these cases to ensure the virus does not reappear from an undetected reservoir.
The following table outlines how the Oslo patient’s case differs from previous high-profile remissions, such as the “Berlin patient.”
| Feature | The “Berlin Patient” & Others | The “Oslo Patient” |
|---|---|---|
| Donor Relationship | Unrelated donor | Sibling donor |
| Primary Motivation | Hematologic Cancer | Myelodysplastic Syndrome |
| Genetic Key | CCR5Δ32 mutation | CCR5 mutation |
| Systemic Result | Immune replacement | Complete chimerism (including gut) |
The Path to a Scalable Cure
Despite the success in Oslo, the medical community is cautious about framing this as a viable treatment for the general population. A stem cell transplant is an invasive, costly, and high-risk procedure with a significant mortality rate, typically reserved for patients with end-stage blood cancers.
the CCR5Δ32 mutation is rare, meaning the vast majority of HIV patients would not find a compatible donor capable of providing this specific resistance. However, the “Oslo patient” provides critical data on how the virus can be eliminated from the gut reservoir, which remains the biggest hurdle in HIV research.
The IciStem consortium, an international research effort, has been monitoring 40 people with HIV who received stem cell transplants for other reasons. Of those, four have been able to stop their medication while remaining undetectable. When combined with six other documented cases outside the consortium, the global total reaches 10.
Javier Martínez-Picado, a researcher at IrsiCaixa in Spain, noted that these results are not coincidental but the product of over a decade of international collaboration. By studying these exceptional cases, scientists hope to develop safer, more accessible therapies—such as gene editing—that can mimic the CCR5 mutation without the need for a full bone marrow transplant.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult with their healthcare provider regarding HIV treatment and stem cell procedures.
The next phase for the IciStem consortium involves the continued monitoring of its current cohort to determine if more patients can safely interrupt their antiretroviral therapy. Researchers are specifically looking for the stability of viral suppression over longer periods to refine the criteria for what constitutes a permanent remission.
We invite you to share this story and join the conversation in the comments below.
